Methods of treating an overweight subject

Abstract

The invention generally relates in part to methods of effecting weight loss and/or improving glucose tolerance in a patient in need thereof, comprising administering a MetAP2 inhibitor.

What is claimed is: 
     
         1 . A method of effecting weight loss in a patient in need thereof, comprising administering a pharmaceutically effective amount of a MetAP2 inhibitor to the patient, wherein upon discontinuation of administration of said MetAP2 inhibitor, the patient has durable weight loss maintained at least for about 1 month. 
     
     
         2 . The method of  claim 1 , wherein the durable weight loss is maintained for at least about 3 months. 
     
     
         3 . The method of  claim 1 , wherein the patient is overweight or obese. 
     
     
         4 . A method of inhibiting further weight gain in an overweight or obese patient, comprising administering a pharmaceutically effective amount of a MetAP2 inhibitor to the patient. 
     
     
         5 . The method of  claim 4 , wherein the patient is overweight. 
     
     
         6 . The method of  claim 5 , wherein the patient is not obese. 
     
     
         7 . A method of increasing and/or improving glucose tolerance and /or glycemic control in a patient in need thereof, comprising administering a pharmaceutically effective amount of a MetAP2 inhibitor to the patient. 
     
     
         8 . The method of  claim 7 , wherein the patient is suffering from type 2 diabetes. 
     
     
         9 . The method of  claim 7 , wherein the patient has impaired glucose tolerance and/or impaired fasting glucose. 
     
     
         10 . The method of  claim 1 , wherein said MetAP2 inhibitor is administered alone or in combination with another active agent. 
     
     
         11 . The method of  claim 1 , wherein said MetAP2 inhibitor is administered buccally, sublingually or transdermally. 
     
     
         12 . The method of  claim 1 , wherein said MetAP2 inhibitor is administered subcutaneously or intravenously. 
     
     
         13 . The method of  claim 1 , wherein said MetAP2 inhibitor is administered via inhalation. 
     
     
         14 . The method of  claim 1 , wherein said MetAP2 inhibitor is administered rectally. 
     
     
         15 . The method of  claim 1 , wherein said MetAP2 inhibitor is a substantially irreversible inhibitor. 
     
     
         16 . The method of  claim 1 , wherein said MetAP2 inhibitor is selected from the group consisting of a fumagillin, fumagillol or fumagillin ketone derivative, siRNA, shRNA, an antibody, or a antisense compound. 
     
     
         17 . The method of  claim 1 , wherein said MetAP2 inhibitor is selected from O-(4-dimethylaminoethoxycinnamoyl)fumagillol and pharmaceutically acceptable salts thereof 
     
     
         18 . The method of  claim 1 , wherein said non-parenterally administering results in decreased body fat and a substantial maintenance of muscle mass in said patient. 
     
     
         19 . The method of  claim 1 , wherein upon administration, fat oxidation is enhanced as compared to a patient on a restricted food intake diet alone. 
     
     
         20 . A method for reducing the amount or frequency of administering supplemental insulin in a patient suffering from type 2 diabetes, comprising a pharmaceutically effective amount of a MetAP2 inhibitor. 
     
     
         21 . A method of maintaining a specified weight in a formerly obese patient, comprising administering a pharmaceutically effective amount of a MetAP2 inhibitor to said patient. 
     
     
         22 . The method of  claim 21 , wherein the pharmaceutically effective amount is less as compared to the amount needed to reduce weight or body fat. 
     
     
         23 . The method of  claim 20 , wherein said pharmaceutically effective amount does not substantially modulate or suppress angiogenesis. 
     
     
         24 . The method of  claim 20 , wherein said MetAP2 inhibitor is a substantially irreversible inhibitor. 
     
     
         25 . The method of  claim 20 , wherein said MetAP2 inhibitor is selected from the group consisting of a fumagillin, fumagillol or fumagillin ketone derivative, siRNA, shRNA, an antibody, or an antisense compound. 
     
     
         26 . The method of  claim 20 , wherein said MetAP2 inhibitor is selected from O-(4-dimethylaminoethoxycinnamoyl)fumagillol and pharmaceutically acceptable salts thereof. 
     
     
         27 . The method of  claim 1 , further comprising co-administering an additional weight loss agent. 
     
     
         28 . The method of  claim 1 , further comprising administering a food restricted diet to said patient. 
     
     
         29 . The method of  claim 1 , wherein said administration occurs at least daily. 
     
     
         30 . The method of  claim 1 , wherein said administration occurs at least weekly.